Ann Dermatol.  2016 Feb;28(1):124-125. 10.5021/ad.2016.28.1.124.

Treatment for Refractory Pruritus Using Oral Aprepitant

Affiliations
  • 1Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea. zooooz@hanmail.net
  • 2Department of Dermatology, Graduate School, Kyung Hee University, Seoul, Korea.

Abstract

No abstract available.


MeSH Terms

Pruritus*

Figure

  • Fig. 1 (A) Multiple excoriated papules and linear excoriations on the trunk before treatment. (B) At the 6-week follow-up, the excoriated papules and linear excoriations appear to be significantly improved.


Reference

1. Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges. 2014; 12:557–559.
Article
2. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010; 5:e10968.
Article
3. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012; 13:1020–1024.
Article
4. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011; 164:665–667.
Article
5. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010; 363:397–398.
Article
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr